Expression of heparanase mRNA in bovine placenta during gestation

K. Kizaki, H. Nakano, H. Nakano, T. Takahashi, K. Imai and K. Hashizume*

Laboratory of Reproductive Endocrinology, Department of Animal Reproduction, National Institute of Animal Industry, Tsukuba-norindanchi, PO Box 5, Tsukuba, Ibaraki 305-0901, Japan

This study reports the identification and sequence of a partial cDNA for bovine heparanase and the expression of its mRNA in the placenta during gestation. The 364 amino acid residues deduced from the 1092 bp cDNA fragment share 81.9% and 80.5% identity with amino acid sequences of human and rat heparanase, respectively. Northern blot hybridization showed that two mRNAs (2.0 and 3.5 kb) are strongly expressed in placenta, and weakly expressed in the kidney, lung, spleen and non-pregnant uterus. In the placenta, these transcripts were detected in the cotyledon at all stages of gestation examined, and in the intercotyledonary fetal membrane and caruncle on day 60, day 120 and day 260. Quantitative real-time RT–PCR analysis showed very low expression of heparanase mRNA in the conceptus before implantation (day 17), but high expression in the cotyledon-containing fetal membrane (days 27–34) after implantation. Furthermore, heparanase mRNA was detected in the cotyledon, intercotyledonary fetal membrane and caruncle after days 60–64 of gestation. However, no significant expression of heparanase mRNA was observed in intercaruncular endometrium at all stages of gestation examined. These results demonstrate that heparanase mRNA is expressed in the placentome, indicating that heparanase may play a role in implantation, and in placental development and function.

Introduction

Heparan sulphate proteoglycans (HSPGs) play a role in various physiological processes such as cell adhesion, migration, differentiation and proliferation (Wight et al., 1992; Taipale and Keski-Oja, 1997). HSPGs reside at the surface of the plasma membrane as well as in the extracellular matrix (ECM) of various types of cell (Kjellen and Lindah, 1991). Heparan sulphate interacts with ECM components such as collagen, laminin and fibronectin, and many growth factors that are also found in the ECM, such as basic fibroblast growth factor, vascular endothelial growth factor and platelet-derived growth factor (Wight et al., 1992; Taipale and Keski-Oja, 1997). Heparanase is an endo-β-d-glucuronidase that degrades heparan sulphate side chains of HSPGs in the ECM (Nakajima et al., 1983, 1984). Several groups have reported detection of heparanase activity in various tumour cells, platelets and placenta (Nakajima et al., 1983, 1984; Vlodavsky et al., 1983; Goshen et al., 1996; Freeman and Parish, 1998). Expression of heparanase is correlated with the metastatic potential of tumour cells as well as that acquired by cells transected with human heparanase cDNA (Vlodavsky et al., 1999). These findings indicate that heparanase-mediated degradation of heparan sulphate in the ECM may be critical during cell invasion associated with tumour metastasis and inflammation (Bartlett et al., 1995; Vlodavsky et al., 1999).

Remodelling of the ECM occurs during implantation and placental development in the uterus (Cross et al., 1994; Wooding and Flint, 1994). Studies show that the ECM-degrading proteinases, such as matrix metalloproteinase-9 and urokinase-type plasminogen activator, are potential major regulators during implantation and placental development (Librach et al., 1991; Behrendtson et al., 1992; Zhang et al., 1996). Although there are no reports that heparanase plays a role in these events in any species, HSPG degradation may be essential in these processes since heparanase is strongly expressed in human placenta (Hulett et al., 1999; Kussie et al., 1999).

The cloning of human heparanase cDNA has been reported (Hulett et al., 1999; Kussie et al., 1999; Vlodavsky et al., 1999; Toyoshima and Nakajima, 1999), as has the tissue distribution of its mRNA expression (Hulett et al., 1999; Kussie et al., 1999). The aim of the present study, was to clone a cDNA encoding a portion of bovine heparanase and determine the expression of heperanase mRNA in bovine placenta during gestation.
Materials and Methods

Materials

Reagents were purchased from Wako Pure Chemical Industries (Osaka), unless otherwise indicated. ISOGEN was purchased from Nippon gene (Toyama). Super Script™ II reverse transcriptase and first strand cDNA synthesis kit were obtained from Life Technologies, Inc. (Rockville, MD). DNA ligation kit, RACE kit and restriction enzymes were purchased from Takara Shuzo Co. (Kyoto). pBluescript SK(+) cloning vector was purchased from Stratagene (La Jolla, CA). AmpliTaq gold DNA polymerase, TaqMan gold RT–PCR kit and dye terminator sequencing kit were purchased from Perkin-Elmer Applied Biosystems (Foster City, CA). pGEM-T easy vector was purchased from Promega (Madison, WI). cis-ACTG primers were designed (5′-CTGAAAGGCTGGAGAGAGTAT-3′ and 5′-CATTGATTTGGAAGATTTGGA-3′). PCR reaction mixes contained cDNA template, 0.5 μmol primers l⁻¹, 0.2 mmol deoxynucleotide l⁻¹ mixture and 0.1 U AmpliTaq gold DNA polymerase μl⁻¹ were placed in a thermal cycler (MJ Research, Inc., Watertown, MA) under the following conditions (in order of denaturation, annealing and extension): 93°C for 30 s, 60°C for 30 s and 72°C for 1 min. Amplified cDNA products were treated with T4 polyadenylate kinase, and then subcloned (using the DNA ligation kit) into pBluescript SK(+) that had been digested with EcoR V and calf intestine alkaline phosphatase. DNA sequencing was performed with both T7 and T3 primers using the dye terminator sequencing kit. After determination of cDNA sequence, 5′- and 3′-rapid amplification of cDNA ends (RACE) was performed using the RACE kit according to the manufacturer's instructions. The resulting cDNA fragments were subcloned into pGEM-T easy vector and sequenced as described above.

RT–PCR was also performed using primers for bovine placental lactogen (Schuler et al., 1988) and β-actin (Degen et al., 1983) cDNAs, under the conditions described above. Two amplified cDNA products for placental lactogen were detected and lower molecular mass product represented an alternatively spliced variant (Kessler and Schuler et al., 1991). Amplified cDNA products for β-actin (892 bp) were subcloned into pBluescript SK(+) as described above.

Hybridization probe

DIG-labelled single strand cRNA probes were prepared using a DIG RNA labelling kit according to the manufacturer’s instructions. Briefly, the cDNA fragment of bovine heparanase (643 bp) was subcloned into the Hind III-EcoR I sites of the pSPT 18 vector. The resultant plasmid was either linearized with Hind III followed by transcription with T7 RNA polymerase to generate the antisense probe, or linearized with EcoR I followed by transcription with SP6 RNA polymerase to generate the sense probe. DIG-labelled β-actin cRNA probe was prepared using the same method.

Northern blot hybridization

Northern blot hybridization was performed as described by Ishii et al. (1996). Total RNA (10 μg) was fractionated on a 1.2% (w/v) agarose–formaldehyde gel. RNA was transferred overnight by capillary action in 20 × standard saline citrate (20 × SSC: 3.0 mol NaCl l⁻¹, 0.3 mol sodium citrate l⁻¹, pH 7.4) on to a positively charged nylon filter and immobilized by UV irradiation. The filter was prehybridized for 1 h in hybridization buffer consisting of 50% (v/v) formamide, 5 × SSC, 2% (w/v) blocking reagent (Roche Molecular Biochemicals), 0.1 mg yeast tRNA ml⁻¹, 0.1% (w/v) N-lauroyl sarcosine and 0.1% (w/v) SDS. Hybridization was performed with a DIG-labelled cRNA probe in hybridization buffer at 68°C overnight. After hybridization, the filter was washed twice with 2 × SSC containing 0.1% (w/v) SDS for 15 min at room temperature, followed by two washes each of 30 min in 0.1 × SSC containing 0.1% (w/v) SDS at 68°C. The filter was then incubated for 1 h in 0.1 mol maleic acid l⁻¹ and 0.15 mol...
NaCl 1\(^{-1}\) containing 1% (w/v) blocking reagent (blocking buffer), and incubated further in anti-DIG alkaline phosphatase-conjugate antibody diluted 1:10,000 in blocking buffer. After 1 h, the filter was washed three times with 0.1 mol maleic acid 1\(^{-1}\) and 0.15 mol NaCl 1\(^{-1}\) containing 0.3% (w/v) Tween 20 for 15 min at room temperature followed by 5 min of rinsing in 0.1 mol Tris–HCl 1\(^{-1}\) (pH 9.5) containing 0.15 mol NaCl 1\(^{-1}\) and 50.0 mmol MgCl\(_2\) 1\(^{-1}\). For signal detection, the filter was incubated for 5 min in 0.25 mmol CDP-star\(^{58}\) 1\(^{-1}\) as a chemiluminescent substrate, and exposed to Kodak XAR-5 film for 1–20 min.

**Real-time RT–PCR analysis**

This novel technique has been used to monitor mRNA expression quantitatively and was described in detail by Heid et al. (1996) and Gerber et al. (1997). Briefly, 50.0 ng total RNA was reverse transcribed with 12.5 U MultiScribe\(^{\text{TM}}\) reverse transcriptase in the presence of 2.5 μmol Oligo dT primer 1\(^{-1}\), 500.0 μmol deoxynucleotide 1\(^{-1}\) mixture, 5.5 mmol MgCl\(_2\) 1\(^{-1}\) and 20 μl RNase inhibitor at 48°C for 30 min. After heat inactivation of reverse transcriptase at 95°C for 5 min, PCR and the resulting relative increase in reporter fluorescent dye emission were monitored in real-time using the 7700 sequence detector (Perkin-Elmer Applied Biosystems). Primers and oligonucleotide probes labelled with a reporter fluorescent dye at the 5’-end and a quencher fluorescent dye at the 3’-end were designed by the Primer Express Program (Perkin-Elmer Applied Biosystems). The primers and probes were as follows: heparanase forward primer 5’-GACCCCTCAAGAAGGTGTTGCT-3’, reverse primer 5’-GCGGACAGGCCCAATTAT-3’ and probe 5’-TGTCACACGTTGCTGGCTTTA-3’; glyceraldehyde-3-phosphate dehydrogenase (GAPDH) forward primer 5’-AAGGCCATCACCATCTTCCA-3’, reverse primer 5’-CCATACATGACCCAGCAT-3’ and probe 5’-AGCCAGATGGCCCAACATGTTTG-3’. The thermal cycling conditions included one cycle at 50°C for 2 min, one cycle at 95°C for 10 min and 45 cycles at 95°C for 15 s and at 60°C for 1 min. The standard curves for each gene were generated by serial dilution of the total RNA isolated from cotyledon at day 60 of gestation.

**Cell preparation**

Briefly, bovine fetal cotyledon at day 240 of gestation was minced and digested with collagenase, and the resultant cell suspension was fractionated using Percoll discontinuous density gradient (1.03–1.08 g ml\(^{-1}\)) centrifugation at 800 g for 20 min at room temperature. Binucleate cells sedimenting at the density range 1.05–1.06 g ml\(^{-1}\) were separated and cultured with Dulbecco’s modified Eagle’s medium–F12 at 95°C for 20 min at room temperature followed by 5 min of rinsing in 0.1 mol Tris–HCl 1\(^{-1}\) (pH 9.5) containing 0.15 mol NaCl 1\(^{-1}\) and 50.0 mmol MgCl\(_2\) 1\(^{-1}\). Differences were considered significant at P < 0.05.

**Results**

**Partial cloning of heparanase cDNA from the bovine placenta**

The cDNA fragment of bovine heparanase, corresponding to the C-terminal coding region of human and rat heparanase (Hulett et al., 1999), was amplified using a first strand cDNA from fetal cotyledonary tissue of bovine placenta at day 60 of gestation. A 643 bp cDNA fragment was obtained using a PCR approach with primers based on the human heparanase sequence, showing high homology (> 80%) with human and rat heparanase cDNA. On the basis of the 643 bp cDNA sequence, amplification of 5’- and 3’-ends of bovine heparanase cDNA was performed. The partial cDNA consisted of 1125 bp obtained by the RACE procedure, which included an open reading frame of 1092 bp (encoding 364 amino acid residues) followed by a 3’ untranslated region. Alignment of the deduced amino acid sequence of human, rat and bovine heparanase indicated 81.9% and 80.5% identity between human and bovine, and rat and bovine heparanase, respectively (Fig. 1). Conserved potential N-linked glycosylation sites, located at amino acid residues 38 and 280 in bovine heparanase, are also found in human and rat heparanase (Hulett et al., 1999; Kussie et al., 1999; Vlodavsky et al., 1999).

**Tissue distribution of bovine heparanase mRNA**

Northern blot analysis was performed to investigate the distribution of heparanase mRNA in bovine tissues (Fig. 2). DIG-labelled bovine heparanase cRNA detected two mRNA transcripts (2.0 and 3.5 kb) in cotyledonary tissue of the fetal placenta. The intensities of the two mRNA bands indicate that they are present in similar amounts in placental tissue. The 3.5 kb transcript was also detected weakly in the kidney, lung, spleen and non-pregnant uterus. No hybridization was detected in other bovine tissues, including brain, heart and liver, and no signal was obtained when a sense probe was used during hybridization (data not shown).
Fig. 1. Amino acid alignment of human, rat and bovine heparanase. The amino acid sequences of human and rat heparanase were deduced from their full-length cDNAs (human, GenBank accession no. AF165154; rat: GenBank accession no. AF184967). The bovine sequence was deduced from a partial cDNA and lacks the N-terminal region. The nucleotide sequence of bovine heparanase was submitted to the GenBank Database under accession no. AF281160. Shaded residues indicate conserved residues in at least two species. The putative N-linked glycosylation sites of bovine heparanase are indicated by asterisks (amino acids 38 and 280).
Expression of bovine heparanase in placenta

Gestational profile of heparanase mRNA in bovine placenta

Northern blot hybridization showed that the expression of heparanase mRNA in the conceptus from day 17 of gestation was below the limit of detection (Fig. 3). The expression of mRNA was evident in the cotyledon-containing fetal membrane at day 30, and cotyledon, intercotyledonary fetal membrane and caruncle at days 30–260. However, the expression of heparanase mRNA was not detected in the intercaruncular endometrium on days 30–120, although the 3.5 kb transcript was weakly expressed on day 260.

Furthermore, quantitative real-time RT–PCR analysis showed very low expression of heparanase mRNA in the conceptus at day 17 (0.027 ± 0.025 heparanase/GAPDH mRNA). However, significantly higher expression of heparanase mRNA was detected in fetal membranes than in the caruncle and intercaruncle endometrium on days 27–34 of gestation (P < 0.05) (Fig. 4a). However, on days 60–64, the expression of heparanase mRNA in the cotyledon was higher than that in the intercaruncle endometrium (P < 0.05) (Fig. 4b). No significant differences were observed in all placental tissues on days 100–148 (Fig. 4c). On days 215–260, higher expression of heparanase mRNA was detected in the cotyledon and caruncle (Fig. 4d). The heparanase mRNA content in the cotyledon did not change throughout gestation from days 27–34 to days 215–260, but a significant increase was detected in the caruncle as gestation progressed (P < 0.05). Throughout gestation, intercaruncular expression of heparanase mRNA was lower than that in the caruncle.

Expression of heparanase mRNA in binucleate cell-rich fraction

Placental cell fractions were examined by RT–PCR to clarify the source of heparanase. Heparanase mRNA was found in the binucleate cell-rich fraction from cotyledon at day 240 of gestation, but not in cotyledon-derived fibroblasts (Fig. 5). Similarly, expression of placental lactogen mRNA, produced only by binucleate cells (Anthony et al., 1992), was also detected in the cotyledon and the binucleate cell-rich fraction, but not in cotyledon-derived fibroblasts.

Discussion

This study reports the cloning of a partial cDNA of bovine heparanase encoding the C-terminal region of human and rat heparanase (Hulett et al., 1999; Kussie et al., 1999;
The deduced amino acid sequence of bovine heparanase shows 81.9% and 80.5% identity with human and rat heparanase, respectively, indicating that the amino acid residue is highly conserved.

Northern blot analysis of bovine tissues showed that two mRNA transcripts (2.0 and 3.5 kb) were highly expressed in the placenta, as also reported in human tissue (Hulett et al., 1999; Kussie et al., 1999). In humans, heparanase mRNA of the expected size (2.0 kb) was detected only in the placenta among the non-immune tissues tested, but both 4.4 kb and 2.0 kb mRNAs were found in many immune tissues (Hulett et al., 1999). The present study demonstrates that heparanase mRNA is also strongly expressed in bovine placenta, and also indicates that the placenta is the major source of heparanase in bovine species. Recent reports indicate that heparanase plays an immunological role in physiological and pathological states, since human immune tissues as well as tumour tissues express heparanase (Hulett et al., 1999; Vlodavsky et al., 1999). In the present study, bovine immune tissues showed low expression of heparanase, and, therefore, its role remains to be elucidated.

The ruminant placenta is classified as synepitheliochorial (Cross et al., 1994; Wooding and Flint, 1994) and has a cotyledonary organization in which both fetal and maternal villi are discernible as discrete structures (placentome) on the uterine epithelium. In cows, implantation and the formation of the cotyledon begin at about day 20 of gestation (Wooding and Flint, 1994). Intimate contact between maternal and fetal tissues occurs only in the placentome (comprising the fetal cotyledon and maternal caruncle), which is the most highly vascularized portion of the placenta (Wooding and Flint, 1994). In the present study, the expression of heparanase mRNA in the placenta during gestation was examined using northern blot analysis and quantitative real-time RT–PCR. The results showed that heparanase mRNA is expressed in the placenta, which takes the central role of placental function, especially during implantation (Wooding and Flint, 1994).

Although the expression of heparan sulphate-binding angiogenic growth factors in bovine placenta has not been...
determined, the expression of basic fibroblast growth factor and vascular endothelial growth factor has been identified in placenta from many species (Gospodarowicz et al., 1985; Hondermarck et al., 1990; Sharkey et al., 1993; Zheng et al., 1997; Clark et al., 1998; Winther et al., 1999). Heparanase may mediate the liberation or activation of heparan sulphate-binding angiogenic growth factors from the ECM, and the growth factors may act as paracrine factors during angiogenesis at the fetal–maternal interface. In addition, degradation of the ECM of both fetal and maternal cells is required during the remodelling of placentae after attachment (Smith et al., 2000). The present study shows that the expression of heparanase mRNA accords with the timing of cotyledon formation in bovine placenta. As heparanase contributes to cell invasion and angiogenesis through degradation of heparan sulphate in the ECM during metastasis (Nakajima et al., 1983; Vlodavsky et al., 1983, 1999), the present study indicates that heparanase plays a critical role in the migration of trophoblasts during implantation and placental formation.

Although most bovine trophoblast cells are non-invasive, binucleate trophoblast cells may have invasive properties that promote fusion with the uterine epithelium on the caruncle (Cross et al., 1994). The possibility that the binucleate cells express heparanase was examined by collecting the binucleate cell-rich fraction from the cotyledon on day 240 of gestation, and performing RT–PCR for heparanase mRNA. Heparanase mRNA was observed in the binucleate cell-rich fraction as well as in the cotyledon. Immunohistochemistry revealed that heparanase is expressed in invasive extravillous trophoblast cells of human placenta (Dempsey et al., 2000). Invasive trophoblast cells, in a manner similar to that of human extravillous trophoblast cells, bovine binucleate cells and rodent giant cells, may use active enzymes such as heparanase and metalloproteinases for ECM remodelling. However, the possibility that other cells in the bovine placenta produce heparanase cannot be excluded, as the present study does not address directly the localization of heparanase in specific cells. Further studies on cellular localization are necessary to understand trophoblast invasiveness in relation to the function of placental heparanase.

In conclusion, the partial cDNA sequence of bovine heparanase was determined and it was established that the mRNA is expressed specifically in the placentome throughout gestation. This ECM-degrading enzyme may have an important role in cytokine activation during angiogenesis and placentalization in cows.

This work was supported by the Organized Research Combination System from the Science and Technology Agency, by the Co-operative System for Supporting Priority Research from the Japan Science and Technology Corporation, and by the Bio-oriented Technology Research Advancement Institution, Japan. K. Kizaki and H. Nakano are supported by a fellowship from the Japan Science and Technology Corporation.

References


Barletti MB, Underwood PA and Parish CR (1995) Comparative analysis of the ability of leucocytes, endothelial cells and platelets to degrade the subendothelial basement membrane: evidence for cytokine dependence and detection of a novel sulfatase Immunology and Cell Biology 73 113–124


Cross JC, Werb Z and Fisher SJ (1994) Implantation and the placenta: key pieces of the development puzzle Science 266 1508–1518


Hondermarck H, Courty J, Ledoux D, Blancaert V, Barritault D and Boilly B (1990) Evidence of high and low affinity binding sites for basic fibroblast growth factor in mouse placenta Biochemical and Biophysical Research Communications 169 272–281


Downloaded from Bioscientifica.com at 04/05/2019 07:46:47PM via free access


Winther H, Ahmed A and Dantzer V (1999) Immunohistochemical localization of vascular endothelial growth factor (VEGF) and its two specific receptors, Flt-1 and KDR, in the porcine placenta and non-pregnant uterus Placenta 20 35–43


Received 11 September 2000.
First decision 16 October 2000.
Accepted 14 November 2000.